Table 4.

Tumor response per RECIST v1.1

	25 mg (n = 1)	50 mg (n = 3)	75 mg (n = 3)	100 mg (n = 10)	125 mg (n = 10)	150 mg (n = 10)	175 mg (n = 3)	All patients (n = 40)
Best overall response, n (%)
Complete response	0	0	0	0	0	0	0	0
Partial response	0	0	0	0	1 (10.0)	1 (10.0)	0	2 (5.0)
Stable disease	0	2 (66.7)	1 (33.3)	7 (70.0)	4 (40.0)	7 (70.0)	2 (66.7)	23 (57.5)
Progressive disease	1	1 (33.3)	2 (66.7)	3 (30.0)	5 (50.0)	2 (20.0)	1 (33.3)	15 (37.5)
DCR, % (95% CI)	0 (NR)	66.7 (9.4–99.2)	33.3 (0.8–90.6)	70.0 (34.8–93.3)	50.0 (18.7–81.3)	80.0 (44.4–97.5)	66.7 (9.4–99.2)	62.5 (45.8–77.3)

DCR disease control rate, NR not reached, RECIST response evaluation criteria in solid tumors